Entera Bio unveils Phase 3 design for EB613 oral PTH(1 — 34) osteoporosis tablet trial
Entera Bio highlighted Phase 2 analyses of EB613, an oral osteoporosis drug candidate, at the ASBMR 2026 annual meeting. Results were already presented at the meeting, pointing to stronger bone-building effects in higher-risk women than in less severe patients. The update supports a shift toward an “anabolic-first” tre